{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:58Z","timestamp":1790959198711,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1208\/s12249-020-01655-7","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T19:02:26Z","timestamp":1588014146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma"],"prefix":"10.1208","volume":"21","author":[{"given":"Xiaoling","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"issue":"10127","key":"1655_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2018;391(10127):1301\u201314.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"1655_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jhep.2015.09.008","volume":"64","author":"R Dhanasekaran","year":"2016","unstructured":"Dhanasekaran R, Venkatesh SK, Torbenson MS, Roberts LR. Clinical implications of basic research in hepatocellular carcinoma. J Hepatol. 2016;64(3):736\u201345.","journal-title":"J Hepatol"},{"issue":"12","key":"1655_CR3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra1001683","volume":"365","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118\u201327.","journal-title":"N Engl J Med"},{"issue":"5665","key":"1655_CR4","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen TM, Cullis PR, et al. Science (New York, NY). 2004;303(5665):1818\u201322.","journal-title":"Science (New York, NY)"},{"issue":"3","key":"1655_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1208\/s12249-010-9519-4","volume":"11","author":"KS Yadav","year":"2010","unstructured":"Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech. 2010;11(3):1456\u201365.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"1655_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1208\/s12249-013-9943-3","volume":"14","author":"Y Wang","year":"2013","unstructured":"Wang Y, Li P, Kong L. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 2013;14(2):585\u201392.","journal-title":"AAPS PharmSciTech"},{"key":"1655_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release : official journal of the Controlled Release Society. 2000;65:271\u201384.","journal-title":"J Control Release : official journal of the Controlled Release Society"},{"key":"1655_CR8","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"C Bi","year":"2016","unstructured":"Bi C, Wang A, Chu Y, Liu S, Mu H, Liu W, et al. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. Int J Nanomedicine. 2016;11:6547\u201359.","journal-title":"Int J Nanomedicine"},{"issue":"41","key":"1655_CR9","doi-asserted-by":"publisher","first-page":"27465","DOI":"10.1021\/acsami.6b05572","volume":"8","author":"Y Bi","year":"2016","unstructured":"Bi Y, Liu L, Lu Y, Sun T, Shen C, Chen X, et al. T7 peptide-functionalized PEG-PLGA micelles loaded with carmustine for targeting therapy of glioma. ACS Appl Mater Interfaces. 2016;8(41):27465\u201373.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"31","key":"1655_CR10","doi-asserted-by":"publisher","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","volume":"32","author":"J Guo","year":"2011","unstructured":"Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010\u201320.","journal-title":"Biomaterials."},{"issue":"2","key":"1655_CR11","first-page":"389","volume":"52","author":"CH Wu","year":"2018","unstructured":"Wu CH, Lan CH, Wu KL, Wu YM, Jane WN, Hsiao M, et al. Hepatocellular carcinoma-targeted nanoparticles for cancer therapy. Int J Oncol. 2018;52(2):389\u2013401.","journal-title":"Int J Oncol"},{"issue":"3","key":"1655_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1158\/1535-7163.MCT-07-2359","volume":"7","author":"A Lo","year":"2008","unstructured":"Lo A, Lin CT, Wu HC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther. 2008;7(3):579\u201389.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1655_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nmat2992","volume":"10","author":"CS Ashley","year":"2011","unstructured":"Ashley CS, Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10(5):389\u201397.","journal-title":"Nat Mater"},{"issue":"3","key":"1655_CR14","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1021\/nn204102q","volume":"6","author":"CE Ashley","year":"2012","unstructured":"Ashley CE, Carnes EC, Epler KE, Padilla DP, Phillips GK, Castillo RE, et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano. 2012;6(3):2174\u201388.","journal-title":"ACS Nano"},{"issue":"7","key":"1655_CR15","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1021\/nn201397z","volume":"5","author":"CE Ashley","year":"2011","unstructured":"Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano. 2011;5(7):5729\u201345.","journal-title":"ACS Nano"},{"key":"1655_CR16","doi-asserted-by":"publisher","first-page":"33511","DOI":"10.1038\/srep33511","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Hu Y, Xiao J, Liu G, Li X, Zhao Y, et al. Investigation of SP94 Peptide as a specific probe for hepatocellular carcinoma imaging and therapy. Sci Rep. 2016;6:33511.","journal-title":"Sci Rep"},{"issue":"1","key":"1655_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijcard.2007.01.004","volume":"121","author":"TO Cheng","year":"2007","unstructured":"Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol. 2007;121(1):9\u201322.","journal-title":"Int J Cardiol"},{"issue":"4","key":"1655_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2174\/138920007780655441","volume":"8","author":"X Yu","year":"2007","unstructured":"Yu X, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, et al. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer\u2019s disease, across the blood-brain barrier. Curr Drug Metab. 2007;8(4):365\u201378.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"1655_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10495-011-0605-1","volume":"16","author":"JH Kim","year":"2011","unstructured":"Kim JH, Jeong SJ, Kwon TR, Yun SM, Jung JH, Kim M, et al. Cryptotanshinone enhances TNF-\u03b1-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis : an international journal on programmed cell death. 2011;16(7):696\u2013707.","journal-title":"Apoptosis : an international journal on programmed cell death"},{"issue":"5","key":"1655_CR20","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.3892\/mmr.2015.4379","volume":"12","author":"Y Ge","year":"2015","unstructured":"Ge Y, Yang B, Chen Z, Cheng R. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway. Mol Med Rep. 2015;12(5):7782\u20138.","journal-title":"Mol Med Rep"},{"key":"1655_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11010-013-1711-x","volume":"381","author":"L Lu","year":"2013","unstructured":"Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, et al. Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling. Mol Cell Biochem. 2013;381:273\u201382.","journal-title":"Mol Cell Biochem"},{"key":"1655_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.biopha.2016.05.015","volume":"82","author":"T Ye","year":"2016","unstructured":"Ye T, Zhu S, Zhu Y, Feng Q, He B, Xiong Y, et al. Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion. Biomed Pharm = Biomedecine & pharmacotherapie. 2016;82:319\u201326.","journal-title":"Biomed Pharm = Biomedecine & pharmacotherapie"},{"issue":"4","key":"1655_CR23","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/med.21304","volume":"34","author":"X Chen","year":"2014","unstructured":"Chen X, Guo J, Bao J, Lu J, Wang Y. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med Res Rev. 2014;34(4):768\u201394.","journal-title":"Med Res Rev"},{"issue":"7","key":"1655_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00262-019-02338-4","volume":"68","author":"Z Han","year":"2019","unstructured":"Han Z, Liu S, Lin H, Trivett AL, Hannifin S, Yang, et al. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. Cancer Immunol Immunother : CII. 2019;68(7):1073\u201385.","journal-title":"Cancer Immunol Immunother : CII"},{"issue":"4","key":"1655_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10495-013-0929-0","volume":"19","author":"IJ Park","year":"2014","unstructured":"Park IJ, Yang WK, Nam SH, Hong J, Yang KR, Kim J, et al. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis : an international journal on programmed cell death. 2014;19(4):615\u201328.","journal-title":"Apoptosis : an international journal on programmed cell death"},{"key":"1655_CR26","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.2147\/IJN.S138501","volume":"12","author":"X Zhang","year":"2017","unstructured":"Zhang X, Li X, Hua H, Wang A, Liu W, Li Y, et al. Cyclic hexapeptide-conjugated nanoparticles enhance curcumin delivery to glioma tumor cells and tissue. Int J Nanomedicine. 2017;12:5717\u201332.","journal-title":"Int J Nanomedicine"},{"issue":"11","key":"1655_CR27","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1166\/jbn.2014.1982","volume":"10","author":"Y Wang","year":"2014","unstructured":"Wang Y, Song D, Costanza F, Ji G, Fan Z, Cai J, et al. Targeted delivery of tanshinone IIA-conjugated mPEG-PLGA-PLL-cRGD nanoparticles to hepatocellular carcinoma. J Biomed Nanotechnol. 2014;10(11):3244\u201352.","journal-title":"J Biomed Nanotechnol"},{"issue":"30","key":"1655_CR28","doi-asserted-by":"publisher","first-page":"19228","DOI":"10.1021\/acsami.6b03166","volume":"8","author":"J Wang","year":"2016","unstructured":"Wang J, Wang H, Li J, Liu Z, Xie H, Wei X, et al. iRGD-decorated polymeric nanoparticles for the efficient delivery of Vandetanib to hepatocellular carcinoma: preparation and in vitro and in vivo evaluation. ACS Appl Mater Interfaces. 2016;8(30):19228\u201337.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1655_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.08.064","volume":"532","author":"CJ Mart\u00ednez Rivas","year":"2017","unstructured":"Mart\u00ednez Rivas CJ, Tarhini M, Badri W, Miladi K, Greige-Gerges H, Nazari QA, et al. Nanoprecipitation process: from encapsulation to drug delivery. Int J Pharm. 2017;532(1):66\u201381.","journal-title":"Int J Pharm"},{"issue":"2","key":"1655_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","volume":"164","author":"H Maeda","year":"2012","unstructured":"Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release : official journal of the Controlled Release Society. 2012;164(2):138\u201344.","journal-title":"J Control Release : official journal of the Controlled Release Society"},{"issue":"12","key":"1655_CR31","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/tox.22633","volume":"33","author":"JH Chang","year":"2018","unstructured":"Chang JH, Lin CH, Shibu MA, Chou YC, Liu JY, Chou YH, et al. Cryptotanshinone (Dsh-003) from Salvia miltiorrhiza Bunge inhibits prostaglandin E2-induced survival and invasion effects in HA22T hepatocellular carcinoma cells. Environ Toxicol. 2018;33(12):1254\u201360.","journal-title":"Environ Toxicol"},{"key":"1655_CR32","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.colsurfb.2019.06.035","volume":"181","author":"Q Shuai","year":"2019","unstructured":"Shuai Q, Zhao G, Zhang X, Yu B, Leec RJ, Su W-K. Selection of fluorescent dye for tracking biodistribution of paclitaxel in live imaging. Colloids Surf B: Biointerfaces. 2019;181:872\u20138.","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"30","key":"1655_CR33","doi-asserted-by":"publisher","first-page":"50023","DOI":"10.18632\/oncotarget.18483","volume":"8","author":"Z Chen","year":"2017","unstructured":"Chen Z, Zhu R, Zheng J, Chen C, Huang C, Ma J, et al. Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma. Oncotarget. 2017;8(30):50023\u201333.","journal-title":"Oncotarget."},{"issue":"3","key":"1655_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s10495-011-0680-3","volume":"17","author":"IJ Park","year":"2012","unstructured":"Park IJ, Kim MJ, Park OJ, Choe W, Kang I, Kim SS, et al. Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells. Apoptosis : an international journal on programmed cell death. 2012;17(3):248\u201357.","journal-title":"Apoptosis : an international journal on programmed cell death"},{"key":"1655_CR35","doi-asserted-by":"crossref","unstructured":"Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death. J Visual Exp : JoVE 2011(50).","DOI":"10.3791\/2597"},{"issue":"5","key":"1655_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1021\/acs.molpharmaceut.6b00933","volume":"14","author":"A Jain","year":"2017","unstructured":"Jain A, Barve A, Zhao Z, Jin W, Cheng K. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery. Mol Pharm. 2017;14(5):1517\u201327.","journal-title":"Mol Pharm"},{"issue":"1","key":"1655_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nano.2017.08.017","volume":"14","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Li Y, Jain A, Chen Z, Liu H, Jin W, et al. Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. Nanomedicine. 2018;14(1):51\u201361.","journal-title":"Nanomedicine"},{"issue":"11","key":"1655_CR38","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1021\/nn404083m","volume":"7","author":"H Meng","year":"2013","unstructured":"Meng H, Zhao Y, Dong J, Xue M, Lin YS, Ji Z, et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013;7(11):10048\u201365.","journal-title":"ACS Nano"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01655-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-020-01655-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01655-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T23:06:36Z","timestamp":1619478396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-020-01655-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1655"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-01655-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"7 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments involving animals were authorized by the Ethics Committee for Animal Experiments of Guangdong Pharmaceutical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"124"}}